Danish Investors Face Turbulence: What Happened During Novo’s Hell Week?
August 6, 2025
Novo Nordisk’s stock plunged over 30% in four days after it cut its 2024 growth forecast, appointed a new CEO and faced fierce U.S. competition plus political pressure from Washington. The market‐value loss exceeded Denmark’s entire GDP, leaving Danish investors cautious and new CEO Mike Doustdar tasked with restoring U.S. performance and investor confidence.
